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Sminmnary In vitro and in vivo studies have suggested synergistic anti-tumour activity of combined hyperther-
mia and tumour necrosis factor alpha (TNF-a). However, some studies indicated an increased systemic toxicity
of TNF by additional hyperthermia. The aim of this study was to obtain starting dosages for a clinical phase I
study on the application of deep local hyperthermia and systemic TNF. We investigated the effect of local
hyperthermia on the toxicity and efficacy of systemic TNF. Rats (Wag/Rij) carrying a subcutaneously
transplanted osteosarcoma in the hind leg received a single intravenous dose of recombinant human (rh)
TNF-m, either at normothermia or at hyperthermia, by positioning the tumour bearing hind leg in a water
bath of 43'C. Dose-effect curves for lethality and tumour cure were established and LD50 and TCD50 values
were caculated. Systemic toxicity was increased by local hyperthermia. The LD5_ values (± s.e.) were 1088
( 61) jig kg-' at normothermia and 205 ( 23) jg kg 'at hyperthermia, resulting in a thermal enhancement
ratio (TER) of 5.3. Following normothermia, tumour cures were observed at TNF concentrations of
1000 -1300jigkg- , while this was observed at doses of 50-300pgkg-' when combined with hyperthermia
(TCD50 values of 1211 and 188 ;g kg- respectively), resulting in a TER of 6.4. Systemic toxicity and
anti-tumour activity of TNF are both increased by local hyperthermia. A safe starting dose for the combined
clinical treatment would be 10% of the dose of TNF-a that has been recommended for phase II studies on
intravenous bolus administration of TNF-a at normothermia. In view of the large variability in tumour
sensitivity for TNF-m, the clinical usefulness of this combined treatment modality has to be determined.
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A decade ago, TNF was considered a promising new drug
for cancer therapy. In vitro and in vivo experiments had
shown a tumour-specific cell killing activity, but thus far the
clinical results have been disappointing (Balkwill et al., 1990).
Severe toxicity of TNF, resembling a toxic shock syndrome,
prevented the administration of dosages required for anti-
tumour activity observed experimentally. Clinically relevant
results were achieved in those situations where TNF could be
administered either locally (van der Schelling et al., 1992) or
regionally, such as by regional isolated perfusion (Lienard et
al., 1992), where the dose level that can be achieved within
tumour tissues is considerably higher than with systemic
administration.
Hyperthermia has been investigated clinically on a large
scale since 1975. The possibilities of applying local hyperther-
mia have been increased by the development of new tech-
niques.
In vitro and in vivo studies strongly suggested synergistic
anti-tumour activity of combined hyperthermia and TNF-m.
In vitro, the addition of hyperthermia was found to enhance
the effect of TNF by a factor (TER = thermal enhancement
ratio) of more than 500 (Watanabe et al., 1988). The effects
of the combination of TNF and hyperthermia in vivo were
also demonstrated to be more than additive (Haranaka et al.,
1987; Amano et al., 1990; Srinivasan et al., 1990; Fujimoto et
al., 1991; Tomasovic et al., 1992).
In view of the experimental findings, combining the two
modalities could be beneficial. However, a possible disadvan-
tage of this combination is that the systemic toxicity of
TNF-a may also be enhanced by additional local hyperther-
mia, as was suggested by the findings of Amano et al. (1990).
All mice treated with the combination of TNF and hyper-
thermia died, whereas all mice treated with TNF at the same
or even higher doses dunrng normothermia survived. In order
to obtain safe starting dosages for a clinical phase I study on
the application of deep local hyperthermia and systemic TNF
treatment, we investigated the toxicity of local hyperthermia
combined with systemic TNF-( as compared with TNF alone
at normal body temperature.
Materials and methods
Animal and tumour system
All procedures involving animals were carried out in accor-
dance with the rules of the institutional Animal Ethical Com-
mittee.
Tumour-bearing female Wag/Rij rats with an average
weight of 160 g were used in this study. The tumour was an
X-ray-induced osteosarcoma in this strain of rats. When the
rats were 12 weeks of age, small pieces of tumour tissue of
about 2 mm3 were transplanted subcutaneously in one thigh.
At about 14 days after transplantation the tumour had
reached a diameter of approximately 1 cm, which was con-
sidered the appropriate size for treatment. Tumour maximum
diameters at the time of treatment ranged from 5 to 17 mm
(mean 12.3, s.d. 2.5 mm) in the normothermia group, and
from 9 to 14mm (mean 11.1, s.d. 1.3 mm) in the hyperther-
mia group. During treatment the animals were anaesthetised
with nembutal, 40 mg kg-' body weight, administered intra-
peritoneally.
Treatment
Single doses of rhTNF-a with a specific activity of
6.7 x 106 U mg-' protein (Knoll, Amsterdam) were given in-
travenously. TNF starting doses were based on prior pre-
clinical testing of TNF in this species at normal temperatures
(experiments performed in our institute, data not published).
After drug administration all animals were placed on a Pers-
pex plate above a warm water bath, and covered with gauzes,
to regain normal body temperature.
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Before TNF administration, in all animals a closed-tip
catheter was placed intrarectally to enable monitoring of
systemic temperature. In all animals of the hyperthermia
group a second catheter was implanted in the tumour, which
allowed registration of two temperatures simultaneously. For
this latter procedure, a considerably longer preparation time
was needed than in the normothermia group. Immediately
following TNF administration, all animals were placed on a
Perspex plate above a warm water bath and covered with
gauzes. Of the animals in the combined TNF + hyperthermia
group, the tumour-bearing hind leg was positioned in the
water bath through a hole in the plate, so that the tumour
was completely submerged. Water temperature was cont-
rolled by a digital bath (model WU 600, Memmert, Ger-
many) at 43 C. Temperature distribution within the bath was
uniform (±+0. C) and ained relatively stable (± 0.2-C)
during the experiments.
The temperature of the waterbath, the systemic
temperature of the animals and tumour temperatures were
continuously monitored using a thermocouple system. This
system was linked with a computer for data storage. Single-
thermocouple probes were used to register rectal
temperatures, while multi-thermocouple probes were
available to monitor tumour temperatures. In each tumour,
temperatures were measured at two sites, with a spacing of
7mm.
Local hyperthermia was applied for 60 min after an intra-
tumour temperature of 42-C had been achieved, or following
a preheating period of maximum 30 mm. During the hyper-
thermia treatment the rectal temperature was allowed to
increase to 39.5 C at most. Further increase in body
temperature was prevented by removing the covering gauzes,
isolating the body from the Perspex plate and/or wetting the
skin with cold water.
Toxicity
Lethality within 48 h after treatment was used as an estimate
of severe toxicity. The incidence of lethality was used to
establish dose-response curves for lethality by logistic
analysis, for both treatment arms. For the two separate
dose-lethality curves, 8-9 dose levels were used with 4-11
rats per TNF dose level. From these dose-lethality curves,
LD,, and LD,O values, the TNF doses resulting in 50% and
10% lethality, respectively, were calculated.
Twnour response
The tumour response was determined by assessing changes in
tumour volume, which was calulated from the three tumour
diameters. Tumour diameters were measured three times a
week using calipers.
Tumour cure, defined as complete tumour regression for a
duration of at least 90 days, was used as the end point.
Dose-response curves were established by logistic analysis,
and TCD50 and TCD,O values (± s.e.) were calculated. The
TCD5o and TCD,O values represent the TNF doses required
to obtain 50% and 10% tumour cure respectively.
Data analysis
Dose-response relationships were evaluated by maximum
likelihood estimation using a multivariate logistic regression
model (statistical software package STATA). Manual step-
wise regression was performed to establish the signifi of
including variables using the likelihood ratio as test criterion.
Resuls
Thermometry
The various rectal and tumour temperatures are presented in
Table I. The rectal temperature at the time that TNF was
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administered (rectal at start) had decreased in all animals
owing to the anaesthesia. The mean rectal temperature
(± s.e.) in the normothermia group was 36.72 ± 0.1 1C,
which was 2C higher than measured at the start of treat-
ment. The maximum rectal temperature was 38.11 ± O.lOC,
which is within the range of normal systemic temperature in
unanaesthetised rats (i.e. 37.5-38.5 C). In the hyperthermia
group the mean rectal temperature measured was
38.28 ± 0.06°C (range 36.6-39.0°C). The mean temperature
at the start of hyperthermia treatment (32.7 ± 0.15°C) was
lower than in the normothermia group, because of a longer
preparation time needed for the introduction of the intra-
tumour catheters for thermometry. The maximum rectal
temperature of 38.9 ± 0.05°C (range 38.2-39.6°C) in this
group of animals was slightly above the normal systemic.
temperature. The time required to achieve 42°C within the
tumour ranged from 6 to 51 min (mean 29, s.e. 1.5 min). The
mean tumour temperature during the 1 h hyperthermia treat-
ment was 42.35 ± 0.02C (range 42.0-42.7C), with a max-
imum of 42.67 ± 0.03°C (range 42.2-43.1-C). The intra-
tumour temperature difference ranged from 0 to 0.5C (mean
0.2, s.d. 0.1C).
Toxicity
Following the administration of TNF at concentrations of
200-1.400 igkg-' at normothermia, 24 rats out of 64 died
within 48 h (Table II). Dose-response curves for lethality are
presented in Figure 1. The caklulated LD,,± s.e. was
1088 ± 61 zg kg-'. The addition of local hyperthermia to
TNF increased lethality significantly: in the dose range
25-1000#Lgkg-' 27 rats out of 61 died, yielding a
LD50±s.e. of 205±23pgkg-'. The thermal enhancement
ratio (TER) at the LD50 level was 5.3 (95% confidence
interval 4.5-6.3, (Table III), while this was 8.7 (4.7-6.3) at
the LDIo level. In a control group of seven rats, no deaths
were observed following the administration of local hyper-
thermia alone.
Twnour response
Following the administration ofTNF at doses of 800 .tgkg-'
and more at normothermia, the macroscopic appearance of
the tumour changed rapidly. Within 1 day after drug
administration the tumour tured black, and it regressed
within 3 days. Following TNF alone four cures were
observed out of 40 surviving animals (Table II). The
dose-response relationship is presented in Figure 2. A TCD50
(±s.e.) of 1211±89 g kg-' was caulated. TNF in com-
bination with hyperthermia resulted in eight cures out of a
total of 34 surviving animals (Table II). The caculated
TCD_% (± s.e.) of the combined treatment was
188 ± 31 jgkg-'. Therefore, the TER for tumour cure at the
TCD_% level was 6.4 (5.1-8.3), and at the TCD,O level it was
12.0 (8.0-21.1) (Table III).
Multivarite logistic analysis
In addition to the TNF dose, several other factors may be
expected to influence tumour cure rate, the incidence of
ethality or both. The influence ofTNF dose, tumour volume
(taken as the logarithm), maximum and mean rectal
Table I Temperatures achieved during treatment with TNF with or
without hyperthermia treatment
TNF at normothermia TNF at hyperdtrmia
(n = 55) (n = 61)
Temperatures (-C) Mean s.e. Mean s.e.
Rectal at start 34.78 0.19 32.72 0.15
Rectal mean 36.72 0.11 38.28 0.06
Rectal max 38.11 0.10 38.93 0.05
Tumour mean 42.35 0.02
Tumour max 42.67 0.03
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Table n Incidence of lethality and tumour cure for various TNF-n concentrations
with or without hyperthermia
TNF TNF (fLgkg-')
(fg kg-'} Lethality Tumour cure +hYperthermia Lethalitr Tumour cure
200 0 5 0 5 25 0 5 0 5
400 0 5 0 5 50 0 8 1 8
600 2 7 0 5 100 19 1 8
800 2 9 0 7 150 3 11 2 8
1000 0 10 1 10 200 7 9 1 2
1100 510 25 300 69 33
1200 6,8 02 600 44 -
1300 89 11 1000 66 -
1400 1 1 -
Table HII Concentrations of TNF-a with or without hyperthermia, and thermal
enhancement ratios for lethality (LD) and tumour cure (TCD) at the 50% and 10%
incidence level
Incidence TNF-x TNF-c (flgkg Thermal enhancement ratio
level (jlgkg-) +hhiperthermia (95% confidence limits)
LD5 ± s.e. 1088 ± 61 205 ± 23 5.3 (4.5-6.3)
LD,O± s.e. 661 ± 139 76 35 8.7 (4.7-19.3)
TCDo +s.e. 1211 89 188 31 6.4 (5.1 -8.3)
TCD,O s.e. 998 76 83 32 12.0 (8.0-21.1)
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temperature. maximum and mean tumour temperature and
rate of temperature increase, measured as the time needed to
reach 42'C, were assessed using multivariate logistic models.
In a few experiments temperatures were measured but not
recorded owing to software failure. Therefore, in all mul-
tivariate models only those animals were included for which
a complete data set was available (for tumour cure: TNF
+ HT, n = 28; TNF alone, n = 28; for lethality: TNF + HT,
n = 47; TNF alone. n = 53). For this reduced number of
animals, the TNF dose-effect relationship remained
significant for the two types of treatment in the univariate
model.
The incidence of lethality after TNF with or without
hyperthermia was not influenced by tumour volume or by
systemic (rectal) temperatures. In the combined therapy
group. a significant effect of both maximum and mean
tumour temperature on the death of the animals was
observed (P = 0.037 and P = 0.047 respectively). The analysis
indicated a decrease in the LD50 of TNF at a further increase
in temperature. If. for instance, the maximum tumour
temperature were to be increased from 42'C to 43'C, the
LD50 value of TNF would decrease by a factor 3.6, from 454
to 126 Lg kg-'. The maximum tumour temperature was also
significant (P = 0.016) in a univariate model, although
inspection of the raw temperature data did not reveal a
significant difference. Division of the relatively short range of
temperatures (42.2-43.1 'C) into two categories of approx-
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Figre 2 Dose-effect relationships for TNF-a induced local
tumour control. Data for TNF at normothermia (U) and for
TNF at hyperthermia (A). Bars = 95% confidence intervals. The
thermal enhancement ratio at the TCD50 level is 6.4.
imately equal size ( 42.6 and >42.6'C) showed 8/24 (33%)
deaths in the low-temperature group, against 17/29 (59%) in
the high-temperature group (P = 0.19).
Tumour cure was not influenced by other factors in addi-
tion to the TNF dose in the group without hyperthermia. In
the group receiving TNF plus hyperthermia however, tumour
volume was an additional factor (P = 0.0009). Incorporating
both TNF dose and tumour volume in the calculation of
TCD50 values, the following doses were obtained: 40, 184,
and 328 ggkg-' for volumes of 250, 500 and 1000mm3
respectively. Addition of temperature parameters (either
alone or in combination with tumour volume) did not
significantly improve the model containing only the TNF
dose.
Discso. and conDchs
This study was designed to investigate whether local hyper-
thermia would enhance the systemic toxicity of intravenously
administered TNF-a, to determine a safe level for a clinical
phase I study with the combination of deep local hyperther-
mia and systemic TNF.
In our cancer institute, regional deep heating is
administered to patients with the BSD-2000 system (Turner
and Schaefermeyer, 1989). The treatment period of 1 h starts
when the tumour has reached a temperature of 42°C, or,
, , _ .Thermal eamento TFW- induced effects
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alternatively. after a maximum of 30 min heating. In the
normal tissues surrounding the tumour a maximum
temperature of 43C is allowed. Generally. in humans the
systemic temperature increases 1-2°C (van der Ploeg et al..
1992). For this study. a similar hyperthermia application was
chosen.
In view of experimental findings. demonstrating synergistic
anti-tumour activity of TNF-a and hyperthermia both in
vitro and in vivo. the combination of these two modalities
appears an attractive option. However, the systemic toxicity
of TNF-a may also be enhanced by additional local hyper-
thermia. as was suggested by Amano et al. (1990). who
reported that all 14 mice died following TNF at a dose of
5000 U or higher in combination with local hyperthermia
(20 min at 43.5'C). whereas none of five animals died follow-
ing 10 000 U of TNF at normothermia. Haranaka et al.
(1987) also reported lethal toxicity of TNF in combination
with total body hyperthermia at 41.5°C in mice, whereas no
side-effects were observed at 40°C.
From these studies. however. the ratio of enhancement
cannot be derived. Also. Amano et al. (1990) did not report
on the systemic temperature during local hyperthermia. In
their study. increased systemic temperatures may also have
been responsible for the increased systemic toxicity compared
with the TNF alone treatment. when the systemic
temperature was probably relatively low owing to the anaes-
thesia.
Since it has been reported that the presence of a tumour
may have a considerable impact on the systemic toxicity of
TNF-x (Asher et al.. 1987). a tumour-bearing animal model
was chosen for this study. This also enabled us to investigate
the anti-tumour activity in both treatment arms.
Our results show an enhancement of systemic toxicity as
measured by lethality with a factor 5.3. Since we found no
correlation between the increase in systemic temperature and
lethality rate within the TNF + hyperthermia group. there is
no evidence that this enhanced toxicitv is caused by systemic
hyperthermia.
On the contrary. the finding that the intra-tumour
temperatures correlated positively with lethalitv suggests that
the enhanced systemic toxicity is instigated by local effects of
TNF at increased temperatures at the tumour site. A possible
explanation may be that hy-perthermia triggers the cascade of
events induced by TNF (Tomasovic and Klostergaard. 1989).
The cytocidal effects of hyperthermia are related to
insufficient blood flow in cancer tissues. resulting in areas
with hypoxia and low pH and. secondarily. to damage to
tumour vasculature (Reinhold and Endnrch. 1986). Although
little is known about the precise mode of action. TNF seems
to cause tumour regression also by different mechanisms:
both direct cytotoxic effects as evidenced by in vitro studies
and alteration of the tumour vasculature and or the host
immune system have been demonstrated. Whether increased
damage to tumour vasculature by hyperthermia. or
augmented direct cytotoxicity of TNF. is related to the
enhancement demonstrated in this study remains to be deter-
mined. Since systemic toxicity enhancement is related to local
tumour temperature. and TNF toxicity also appears related
to the presence of a tumour (Asher et al.. 1987). vasoactive
or immunoactive mediators might be released in the circula-
tion as an indirect result of the cytotoxicity by TNF. or the
necrosis induced by the treatment.
Having defined a TER at the LD.O level in these tumour-
bearing Wag Rij rats of 5.3. we estimate that a safe starting
dose of combined systemic TNF and local hyperthermia in
humans would be 10% of the dose that has been recom-
mended for phase II studies with single-agent bolus intra-
venous administration of TNF-z (Blick et al.. 1987: Chap-
man et al.. 1987; Balkwill et al.. 1990: Schiller et al.. 1991).
In our model the anti-tumour effect of TNF-x was
enhanced by a factor 6.4. Whether this modest enhancement
of anti-tumour activity at increased temperatures. as com-
pared with the enhanced toxicity. has clinical usefulness has
to be determined in clinical testing.
Systemic TNF toxicity was found to be enhanced by addi-
tional local hyperthermia. Further. it was found that a 1°C
higher maximum tumour temperature results in a further
decrease in the LD^O dose of TNF by a factor 3.6. These
findings imply that in the clinical situation. when the tumour
temperature distribution generally is difficult to control (van
der Zee et al.. 1986). the combination of systemic TNF and
* wal hypertherinia has to be applied with great caution.
Abbreviations
TER. thermal enhancement ratio; (rh)TNF-m. (recombinant human)
tumour necrosis factor alpha.
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